NavDx
HPV-positive Oropharyngeal Cancer (Detection, Monitoring, Surveillance)
CommercialActive
Key Facts
Indication
HPV-positive Oropharyngeal Cancer (Detection, Monitoring, Surveillance)
Phase
Commercial
Status
Active
Company
About Naveris
Naveris is a private, commercial-stage diagnostics company pioneering liquid biopsy tests for HPV-driven cancers, primarily oropharyngeal and anal squamous cell carcinomas. Its core technology, Tumor Tissue Modified Viral (TTMV)-HPV DNA detection, enables ultrasensitive monitoring of circulating viral DNA, allowing for earlier cancer detection, treatment response monitoring, and recurrence surveillance. With its lead product NavDx® already in clinical use and supported by a growing body of peer-reviewed publications, Naveris is positioned in the high-growth liquid biopsy market, targeting a clear unmet need in oncology care pathways.
View full company profile